8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators

A compound having the formula:

• 10
• wherein:
• R1 is selected from the group of hydrogen, a C1-C6 alkyl, F, Cl, Br, I, NO2, OR2, NR13R14, and SR2;
• R2 is selected from the group of hydrogen, C1-C6 alkyl and C1-C6 alkenyl, wherein the C1-C6 alkyl and C1-C6 alkenyl are optionally substituted with C1-C6 alkyl, arylalkyl, aryl or heteroaryl;
• R3 and R4 each independently is selected from the group of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, aryl, and heteroaryl, wherein the alkyl, haloalkyl, perhaloalkyl, alkenyl, alkynyl, aryl, and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• or
• R3 and R4 taken together form a three- to seven-membered ring optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• R5 and R6 each independently is selected from the group of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, aryl, and heteroaryl, wherein the alkyl, haloalkyl, perhaloalkyl, alkenyl, alkynyl, aryl, and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• or
• R7 and R8 taken together form a ═O, ═NR2 or a three- to seven-membered ring optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• R7 and R8 each independently is selected from the group of hydrogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, aryl, and heteroaryl, wherein the alkyl, haloalkyl, perhaloalkyl, alkenyl, alkynyl, aryl, and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• or
• R7 and R8 taken together form a ═O, ═NR2 or a three- to seven-membered ring optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• R9 is selected from the group of hydrogen, C1-C4 alkyl, F, Cl, Br, I, OR2, NR13R14, and SR2;
• R10 is selected from the group of hydrogen, F, Cl, Br, CF3, CF2OR2, CH2OR2, OR2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, aryl, and heteroaryl, wherein the alkyl, haloalkyl, perhaloalkyl, aryl, and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• R11 is selected from the group of hydrogen, F, Cl, Br, I, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, C1-C6 alkenyl, C1-C6 alkynyl, aryl, and heteroaryl, wherein the alkyl, haloalkyl, perhaloalkyl, alkenyl, alkynyl, aryl, and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• R12 is selected from the group of hydrogen, C(O)R11, SR2, S(O)R13, S(O2)R13, C1-C6 alkyl, C1-C6 alkenyl, aryl, arylalkyl and heteroaryl, wherein the alkyl, alkenyl, aryl, arylalkyl and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• X is selected from the group of hydrogen, F, Cl, Br, I, CN, CF3, SR2, S(O)R13, SO2R13, SO3R13, NR13R14, CF3, NO2, and R13;
• R13 and R14 each independently is selected from the group of hydrogen, C(O)R11, SO2R, C1-C6 alkyl, C1-C6 alkenyl, C1-C6 haloalkyl, C1-C6 perhaloalkyl, aryl, arylalkyl and heteroaryl, wherein the alkyl, alkenyl, haloalkyl, perhaloalkyl, aryl, arylalkyl, and heteroaryl are optionally substituted with hydrogen, F, Cl, Br, C1-C4 alkyl, OR2, NR13R14, or SR2;
• with the proviso that when the dotted line in the ring structure is a double bond, R6 and R7 are null;
• and paharmacuetically accpeptable salts thereof.